Vaxin, a clinical-stage vaccine development company, has been awarded a $21.7m contract by the Office of Biomedical Advanced Research and Development Authority (BARDA) for the development of the company’s proprietary anthrax vaccine, AdVAV.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The award will also support pre-clinical assessment, final manufacturing process development and the supply of clinical materials to support an investigational new filing and first-in-man dose ranging study of AdVAV.
Vaxin president and CEO Bill Enright said the company along with BARDA will accelerate the development of the AdVAV vaccine candidate.
In proof of principle studies, AdVAV vaccine has demonstrated certain characteristics such as protection with a single dose in multiple animal species, safety profile in animals, needle-free administration, rapid onset of and long-lasting immunity, stability for more than two years at refrigerated and frozen temperatures, and rapid and cost-effective manufacturing using an established cell-culture process.
The proof of principle studies were supported by grants from the National Institute of Allergy and Infectious Diseases.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
